Journal: bioRxiv

Article Title: IR-B deficiency and fatty acid dysregulation accelerate prostate cancer progression via PI3K/AKT signaling

doi: 10.64898/2026.01.30.702723

Figure Lengend Snippet: (A) Relative mRNA expression of lipid synthesis-related genes in DLP lobes of LL H and pLL +H mice by qPCR. (B) GPR120 expression in prostate adenocarcinoma (PRAD) stratified by nodal metastasis status, from TCGA data. (C) GPR120 expression based on Gleason score in PRAD patients, TCGA data. (D) Immunofluorescence staining of GPR120 in DLP lobes of Hi-Myc and wild-type mice. Scale bar: 50μm. (E) Western blot of GPR120, GLUT1, GLUT12, p GSK3β-S9, GSK3 β, GSK3α/β, Bcl-2, and BAX in DLP lobes of LL, pLL + , LL H and pLL +H mice. (F) Immunofluorescence of GLUT1 in DLP lobes. Scale bar: 50μm.

Article Snippet: The following primary antibodies were used: IRS, phospho-IRS1(Tyr896), GSK3β and phospho-GSK3β(Ser9), GPR120, GLUT1, Bcl-2, BAX (Abbkine, USA); IR and phospho-IR, AR, AKT1 and phospho-AKT, PI3K p85 alpha, GAPDH (Proteintech, Wuhan, China); Ki-67 (Cell Signaling Technology, USA); GLUT12 (Boster Bioengineering Co., Ltd., Wuhan); GSK3α/β and phospho-GSK3β (Y216) and phosphor-GSK3α (Y279) (Abcam,USA).

Techniques: Expressing, Immunofluorescence, Staining, Western Blot

Journal: Journal of Translational Medicine

Article Title: Hypoxic BMSCs accelerate femur fracture healing via the METTL3/SLC2A3 m6A-glycolysis axis

doi: 10.1186/s12967-025-07510-2

Figure Lengend Snippet: SLC2A3 enhances osteogenic capacity through the glycolytic pathway. ( A ) Immunofluorescence assay showed the expression level of SLC2A3. ( B - C ) WB analysis of SLC2A3, Runx2, OCN, and Osx expression levels in groups. ( D ) ELISA analysis of ALP levels in groups. ( E ) Alizarin Red staining illustrating osteogenic capacity. ( F ) ATP levels. ( G ) Glucose uptake. ( H ) WB analysis of HK2, PKM2, and LDHA expression levels in groups. ( I ) The detection of extracellular acidification rate (ECAR). ** P < 0.01, *** P < 0.001, one-way ANOVA

Article Snippet: Membranes were incubated with primary antibodies against SLC2A3 (#A03259-2, 1:1000, BOSTER, Wuhan, China), runt-related transcription factor-2 (Runx2, #ab236639, 1:1000, Abcam, Cambridge, MA, USA), osteocalcin (OCN, #ab93876, 1:1000), Osterix (Osx, #A02077-1, 1:1000), hexokinase 2 (HK2, #ab209847, 1:2000), pyruvate kinase muscle isozyme 2 (PKM2, #ab150377, 1:2000), lactate dehydrogenase A (LDHA, #ab112996, 1:1000), METTL3 (#ab195352, 1:1000), METTL4 (#ab261735, 1:1000), METTL4 (#ab309096, 1:1000), and ACTB (#ab8226, 1:5000).

Techniques: Immunofluorescence, Expressing, Enzyme-linked Immunosorbent Assay, Staining

Journal: Journal of Translational Medicine

Article Title: Hypoxic BMSCs accelerate femur fracture healing via the METTL3/SLC2A3 m6A-glycolysis axis

doi: 10.1186/s12967-025-07510-2

Figure Lengend Snippet: METTL3 promotes osteogenic capacity through glycolysis. ( A ) qPCR analysis of the expression level of METTL3 in Ctrl and Hypoxia groups. ( B , D ) WB analysis of the expression levels of METTL3, METTL4, METTL14, SLC2A3, Runx2, OCN, and Osx in groups. ( C , E ) Immunofluorescence assay showed the expression level of METTL3 and SLC2A3. (F) WB analysis of Runx2, OCN, and Osx expression levels. ( G ) ELISA analysis of ALP levels in groups. ( H ) Glucose uptake. ( I ) ATP level. ( J ) Alizarin Red staining detects osteogenic capacity. (K) WB analysis of HK2, PKM2, and LDHA expression levels in groups. ( L ) The detection of ECAR. * P < 0.05, ** P < 0.01, *** P < 0.001, Student’s t -test

Article Snippet: Membranes were incubated with primary antibodies against SLC2A3 (#A03259-2, 1:1000, BOSTER, Wuhan, China), runt-related transcription factor-2 (Runx2, #ab236639, 1:1000, Abcam, Cambridge, MA, USA), osteocalcin (OCN, #ab93876, 1:1000), Osterix (Osx, #A02077-1, 1:1000), hexokinase 2 (HK2, #ab209847, 1:2000), pyruvate kinase muscle isozyme 2 (PKM2, #ab150377, 1:2000), lactate dehydrogenase A (LDHA, #ab112996, 1:1000), METTL3 (#ab195352, 1:1000), METTL4 (#ab261735, 1:1000), METTL4 (#ab309096, 1:1000), and ACTB (#ab8226, 1:5000).

Techniques: Expressing, Immunofluorescence, Enzyme-linked Immunosorbent Assay, Staining

Journal: Journal of Translational Medicine

Article Title: Hypoxic BMSCs accelerate femur fracture healing via the METTL3/SLC2A3 m6A-glycolysis axis

doi: 10.1186/s12967-025-07510-2

Figure Lengend Snippet: BMSC hypoxia promotes METTL3, which facilitates osteogenic capacity by activating the m 6 A modification of SLC2A3. ( A ) After treating cells with 1 µM SAH, RIP-qPCR was employed to detect the m6A modification level on SLC2A3 mRNA. ( B - D ) QPCR, WB and immunofluorescence assay showed the expression level of SLC2A3. ( E ) The detection of ECAR. ( F , J ) WB analysis of METTL3, SLC2A3, Runx2, OCN, and Osx expression levels in transfections. ( G ) ELISA analysis of ALP levels in groups. ( H ) Glucose uptake. ( I ) ATP level. ( K ) Alizarin Red staining detects osteogenic capacity. ( L ) WB analysis of HK2, PKM2, and LDHA expression levels in transfections. ( M ) The detection of ECAR. ***P < 0.001, one-way ANOVA

Article Snippet: Membranes were incubated with primary antibodies against SLC2A3 (#A03259-2, 1:1000, BOSTER, Wuhan, China), runt-related transcription factor-2 (Runx2, #ab236639, 1:1000, Abcam, Cambridge, MA, USA), osteocalcin (OCN, #ab93876, 1:1000), Osterix (Osx, #A02077-1, 1:1000), hexokinase 2 (HK2, #ab209847, 1:2000), pyruvate kinase muscle isozyme 2 (PKM2, #ab150377, 1:2000), lactate dehydrogenase A (LDHA, #ab112996, 1:1000), METTL3 (#ab195352, 1:1000), METTL4 (#ab261735, 1:1000), METTL4 (#ab309096, 1:1000), and ACTB (#ab8226, 1:5000).

Techniques: Modification, Immunofluorescence, Expressing, Transfection, Enzyme-linked Immunosorbent Assay, Staining

Journal: Journal of Translational Medicine

Article Title: Hypoxic BMSCs accelerate femur fracture healing via the METTL3/SLC2A3 m6A-glycolysis axis

doi: 10.1186/s12967-025-07510-2

Figure Lengend Snippet: BMSC hypoxia promotes METTL3 and facilitates osteogenic capacity by activating SLC2A3 m 6 A modification through the glycolytic pathway. ( A ) RIP analysis of the binding relationship between SLC2A3 and METTL3. ( B ) Pull-down analysis of the association between SLC2A3 and METTL3. ( C - D ) WB analysis of SLC2A3, Runx2, OCN, and Osx expression levels in transfections. ( E ) Glucose uptake. ( F ) ATP levels. ( G ) WB analysis of HK2, PKM2, and LDHA expression levels in transfections. ( H ) Alizarin Red staining to detect osteogenic capacity. *** P < 0.001, Student’s t-test

Article Snippet: Membranes were incubated with primary antibodies against SLC2A3 (#A03259-2, 1:1000, BOSTER, Wuhan, China), runt-related transcription factor-2 (Runx2, #ab236639, 1:1000, Abcam, Cambridge, MA, USA), osteocalcin (OCN, #ab93876, 1:1000), Osterix (Osx, #A02077-1, 1:1000), hexokinase 2 (HK2, #ab209847, 1:2000), pyruvate kinase muscle isozyme 2 (PKM2, #ab150377, 1:2000), lactate dehydrogenase A (LDHA, #ab112996, 1:1000), METTL3 (#ab195352, 1:1000), METTL4 (#ab261735, 1:1000), METTL4 (#ab309096, 1:1000), and ACTB (#ab8226, 1:5000).

Techniques: Modification, Binding Assay, Expressing, Transfection, Staining

Journal: Journal of Translational Medicine

Article Title: Hypoxic BMSCs accelerate femur fracture healing via the METTL3/SLC2A3 m6A-glycolysis axis

doi: 10.1186/s12967-025-07510-2

Figure Lengend Snippet: SLC2A3 overexpression promotes fracture healing. ( A ) X-ray images of bone defects in rat models of the different groups after surgery ( n = 3). ( B ) Gross observation of the surgical site in Sprague–Dawley rats ( n = 3). ( C ) Micro-CT analysis of fracture tissues ( n = 3). ( D ) WB analysis of SLC2A3, METTL3, Runx2, HK2, PKM2, and LDHA protein expression levels ( n = 3)

Article Snippet: Membranes were incubated with primary antibodies against SLC2A3 (#A03259-2, 1:1000, BOSTER, Wuhan, China), runt-related transcription factor-2 (Runx2, #ab236639, 1:1000, Abcam, Cambridge, MA, USA), osteocalcin (OCN, #ab93876, 1:1000), Osterix (Osx, #A02077-1, 1:1000), hexokinase 2 (HK2, #ab209847, 1:2000), pyruvate kinase muscle isozyme 2 (PKM2, #ab150377, 1:2000), lactate dehydrogenase A (LDHA, #ab112996, 1:1000), METTL3 (#ab195352, 1:1000), METTL4 (#ab261735, 1:1000), METTL4 (#ab309096, 1:1000), and ACTB (#ab8226, 1:5000).

Techniques: Over Expression, Micro-CT, Expressing